1. Home
  2. With spike of 54,736 cases, India's COVID-19 tally crosses 17 lakh mark

With spike of 54,736 cases, India's COVID-19 tally crosses 17 lakh mark

Agencies
August 2, 2020

New Delhi, Aug 2: India's COVID-19 tally crossed the 17 lakh mark with 54,736 positive cases and 853 deaths reported in the last 24 hours.

"The total COVID-19 cases stand at 17,50,724 including 5,67,730 active cases, 11,45,630 cured/discharged/migrated and 37,364 deaths," said the Union Health and Family Welfare Ministry.

As per the data provided by the Health Ministry, Maharashtra -- the worst affected state from the infection -- has a total of 1,49,214 active cases and 15,316 deaths. A total of 4,31,719 coronavirus cases have been recorded in the state up to Saturday, as per the state health department.

Tamil Nadu has a total of 60,580 active cases and 4,034 deaths.

In Delhi, the total cases rose to 1,36,716, including 1,22,131 recovered/discharged/migrated cases and 3,989 deaths. There are 10,596 active cases in the national capital.

The total number of COVID-19 samples tested up to August 1 is 1,98,21,831 including 4,63,172 samples tested yesterday, said the Indian Council of Medical Research (ICMR) on Sunday.

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 9,2020

New Delhi, Jan 9: JNU students who tried to march towards the Rashtrapati Bhavan on Thursday protesting the violence on the university campus were stopped by police and later detained.

The police also resorted to baton charge to control the mob who tried to block the traffic at Janpath. Using loudspeakers, the police also appealed to the crowd to maintain peace.

Before the students tried to proceed towards the Rashtrapati Bhavan, a delegation of JNU Students' Union and JNU Teachers' Association also met Human Resource Development (HRD) Ministry officials and demanded the removal of Vice-Chancellor M Jagadesh Kumar from his post.

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 2,2020

Lucknow, Aug 2: Uttar Pradesh's cabinet minister for Technical Education Kamal Rani Varun succumbed to COVID-19 on Sunday at the Sanjay Gandhi Postgraduate Institute of Medical Sciences.

Kamal Rani is the first minister in Uttar Pradesh to die after contracting coronavirus. She was 62.

On 18 July, the minister tested positive for coronavirus and was admitted to the Shyama Prasad Mukherjee Hospital.

She was later shifted to the Sanjay Gandhi Postgraduate Institute of Medical Sciences.

Uttar Pradesh chief minister Yogi Adityanath has expressed grief over the minister's death.

In a condolence message issued on Sunday, Adityanath said, "Kamal Rani Varun died on Sunday at around 9.30 am. She was an experienced and capable leader. She discharged her responsibilities with competence. She was a dedicated public representative, who was always working for the welfare of deprived and oppressed sections of the society."

Kamal Rani was the MLA from Ghatampur in Kanpur. She was also twice a Member of Parliament in the Lok Sabha.

Meanwhile, Adityanath has cancelled his visit to Ayodhya scheduled for the day, Additional Chief Secretary (Home) Awanish Awasthi said on Sunday.

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 3,2020

New Delhi, Jul 3: In a significant step, ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine). It is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government, says ICMR in a statement.

The vaccine is derived from a strain of SARS-CoV-z isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine.

In a letter to the institutes that will be involved in the trails of the vaccine, ICMR has said

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials. BBIL is working expeditiously to meet the target. However, final outcome will depend on the cooperation of all clinical trial sites involved in this project. you have been chosen as a clinical trial site of the BBV152 COVID vaccine. ln view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to initiation of the clinical trial and ensure that the subject enrollment is initiated no later than 7th July 2020."

The ICMR also asked the institutes to comply with the order, "Kindly note that non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on the highest priority and meet the given timelines without any lapse."

The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.